SCHEMBL17405705

SCHEMBL17405705

c1ccc2c(c1)oc1ccc(-n3c4ccccc4c4c5c6ccccc6sc5c5c6ccccc6sc5c43)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
ESR2 Q92731 2/20 0.33
ESR1 P03372 1/20 0.33
AHR P35869 1/20 0.32
TP53 P04637 2/20 0.32
RXFP1 Q9HBX9 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30
CHRNA7 P36544 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17405417 0.98 MAPT (0.35) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL19985926 0.94 MAPT (0.34) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL16275587 0.94 MAPT (0.35) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17228965 0.93 MAPT (0.35) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17406037 0.92 KDM4E (0.33) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17405808 0.92 KDM4E (0.33) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17405840 0.92 MAPT (0.35) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17405557 0.91 ESR2 (0.35) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17405495 0.91 KDM4E (0.34) MAPTSMN1; SMN2KDM4EMEN1NPC1
SCHEMBL17405753 0.91 KDM4E (0.34) MAPTSMN1; SMN2KDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9887367-B2 Heterocyclic compound, material for organic electroluminescent elements using same, organic electroluminescent element using same, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2018-02-06 US disclosed
US-9887367-B2 Heterocyclic compound, material for organic electroluminescent elements using same, organic electroluminescent element using same, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2018-02-06 US disclosed
US-20160005977-A1 HETEROCYCLIC COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME, ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-01-07 US disclosed
US-20160005977-A1 HETEROCYCLIC COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME, ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160005977-A1 HETEROCYCLIC COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME, ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME, AND ELECTRONIC DEVICE ODC1, NOTUM, OR10J3 MAPT 2869/4885SMN1; SMN2 3232/4885KDM4E 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.